Patients who notice no effect by day 7 are unlikely to benefit from continued injections without addressing other metabolic factors
Venter C, Meyer RW, Nwaru BI, Roduit C, Untersmayr E, Adel-Patient K, Agache I, Agostoni C, Akdis CA, Bischoff SC, du Toit G, Feeney M, Frei R, Garn H, Greenhawt M, Hoffmann-Sommergruber K, Lunjani N, Maslin K, Mills C, Muraro A, Pali-Schll I, Poulson LK, Reese I, Renz H, Roberts GC, Smith P, Smolinska S, Sokolowska M, Stanton C, Vlieg-Boerstra B, OMahony L
The delay due to distribution is a pharmacokinetic phenomenon that can account for delays of a few minutes
FDA-approved drugs undergo a long and rigorous process of clinical trials to prove their safety, effectiveness, and quality before they can be marketed to the public. Compounded drugs, even from 503B facilities, do not go through this same pre-market approval process